Kay Olmstead is a co-founder and CEO of Nano PharmaSolutions. Dr. Olmstead has over 31 years of experience in pharmaceutical industry in both API (drug substance) and finished dosage form development.
Prior to founding Nano PharmaSolutions, Dr. Olmstead served numerous small to medium pharmaceutical companies in worldwide as a CMC subject matter expert, especially in poorly soluble drug development. During past 20 years, Dr. Olmstead played a lead role in the development and the FDA approval of five commercial drugs for San Diego based companies, including Santarus, Inc. (NASDAQ: SNTR | acquired by Salix in 2013 for $2.6 billion) and Intercept Pharmaceutical (NASDAQ: ICPT).
Dr. Olmstead has published more than 12 manuscripts and has 11 issued patents and 3 pending patent applications. Dr.Olmstead received Ph.D. degree in Organic Chemistry at Johns Hopkins University followed by a NIH post-doctoral fellowship at Stanford University. She currently serves on as the Global Pharma Key Opinion Leader for Korean Health Industry Development Institute (KHIDI).
Dr. Seok-Keun Koh is a Co-founder and serves as Chief Technology Officer at Nano PharmaSolutions (NPS). He has graduate degrees in chemistry, physical chemistry and mechanical engineering. He earned his Ph.D. in Materials Science. He developed a unique manufacturing process called NPP (nano particles on powder) which was adapted to pharmaceutics and forms the basis for NPS’ formulation technology. He was an invited speaker at Materials Research Society’s 1995 Fall Meeting, was given a scientific award in 2000 by the Republic of Korea and his technology won honors at the Australasian Society of Clinical Immunology and Allergy (ASCIA) in July of 2000. He has been awarded three patents by the US Patent and Trademark Office.
Mr. Saeyeon Lee is a founding member and COO of NanoPharma Solutions.
He began his career as a medicinal chemist at the Korea Institute of Science and Technology in 2005 and has led the CMC team at pharmaceutical companies over the years. His experience from early to late stages of new drug development focused mainly on developing insoluble small molecule compounds that can be administered to humans.
He is not limited to the development of oral products but has extensive experience in topical and injection formulation.
His unique project management skill creates a synergy effect with his scientific background knowledge and promotes product development within a short period.
He earned his master’s degree in organic chemistry, holds a total of 14 global patents, and participated in researches for five papers, including Nature Medicine. He is also currently working as an independent CMC consultant in South Korea.
Patricia has over thirty year of experience in finance including start-ups as well as publicly traded companies. In her current role as CFO at Nano PharmaSolutions, she is a member of the leadership team developing and executing on financing strategy and responsible for developing administrative operational infrastructure supporting the dynamic growth of the company.
Prior to joining Nano PharmaSolutions, Patricia spent a decade at Pfenex Inc.. (PFNX), beginning with the spin out of the novel protein production platform from the Dow Chemical Company into a stand-alone biotechnology company. She was instrumental in developing and executing on Pfenex’s financial strategy that included an IPO and provided the capital needed to obtain FDA approval on its lead candidate and eventual final exit through acquisition.
Prior to Pfenex Inc, Patricia led finance and corporate development teams in the life science and technology industries of various start-ups and publicly traded companies.
Patricia received her MBA from the University of California, Los Angeles. She holds an active CPA license in the State of California.
Luigi (Lou) Schioppi Nano PharmaSolutions’ VP of Development
Luigi (Lou) Schioppi, NanoPharma Solutions’ VP of Development, graduated from the University of Southern California with a BS degree in Biology. He obtained a MS in biology/biochemistry from the University of California, Riverside. Following a brief stint as a teacher and three years in the family construction business, he was hired as scientist by Baxter-Travenol. Four years later he joined Hybritech, the original biotechnology company in San Diego established in 1978, that pioneered the development of monoclonal antibodies for use in ultra-sensitive and specific diagnostic and therapeutic applications. At Hybritech he was instrumental in the development of the most industry-trusted prostate-specific antigen (PSA) diagnostic test. He also excelled as a six-sigma/excellence trainer of all levels of the organization, manufacturing process optimization specialist, work center supervisor, manufacturing process validation subject matter expert (SME) and ultimately manager of therapeutic antibody production work centers. He then joined Dura Pharmaceuticals, an organization focused on developing proprietary dry-powder inhaler products to replace metered dose inhalers formulated with ozone-depleting propellants. In his role as Sr. Manager of Manufacturing, he oversaw the production of clinical trial materials for numerous big-pharma clients, the expansion of clean-room operations, automation of product manufacturing and packaging operations and raw material/finished product warehousing. Following Dura Pharmaceuticals, he joined Santarus which successfully commercialized an immediate-release formulation of Prilosec. In his capacity as Director of Manufacturing at Santarus, he monitored and provided timely input regarding contract development and manufacturing operations (CDMO) facility expansion, manufacturing equipment acquisition/installation/validation, process validation and product commercialization activities. He then joined Somaxon Pharmaceuticals as Sr. Director of Manufacturing responsible for product formulation optimization, process validation, commercial product manufacturing, third party logistics service provider identification/selection/management, marketing material development/approval/printing and drug product/marketing material inventory management. He then joined a CDMO as a business development (BD) representative where he became the best-selling BD representative in his first year of service. He then joined Halo Pharmaceuticals as BD representative responsible for BD activities along the west coast of US. Following that, he joined BioDuro, San Diego-based CDMO specializing in BCS category 2 and 4 drug substance solubility enhancement technologies, as a technical writer and six-sigma trainer of the manufacturing team. He then joined Apricus Biosciences as Sr. Director of Manufacturing. In this capacity he was responsible for the timely manufacturing and delivery of commercial product, next generation container/closure identification/qualification and implementation of Design Control for a drug product that was designated by the FDA as a drug/device combination product. He is now enthusiastically focused on the global adoption of NanoPharma Solutions’ truly revolutionary and patent-pending pharmaceutical formulation development technology.
Dr. Ingrid Niesman Prof. SDSU
Director of EMF Particle Morphology
Early in her career Dr. Ingrid Niesman performed research for various departments at UC San Diego. In 2014 she joined The Scripps Research Institute (TSRI) as a Postdoctoral Fellow. Dr. Ingrid Niesman is currently Director of San Diego State University’s (SDSU) Electron Microscopy Facility, which is affiliated with the Department of Biology. She has written articles for peer-reviewed journals and is considered an expert in particle analysis using scanning electron microscopy (SEM) and electron dispersive spectroscopy (EDS) as well as two-dimensional and three-dimensional cryo electron microscopy (cryoEM). Her extensive background in cell biology and particle analysis makes her a key member of Nano PharmaSolutions (NPS) Scientific Advisory Board (SAB).
Dr. Micheal Niesman CSO of MingSight Biology & Pharmacology
GM of Daylight Solutions Laser Physics
Dr. Michael Niesman earned his Ph.D. in cell biology at University of Illinois and a Postdoctoral Fellowship at Louisiana State University. In the mid-1990s he was Assistant Professor of Ophthalmology, Pharmacology and Toxicology at University of Arkansas for Medical Scientist. He was Head of Ocular Pharmacology at Warner Lambert, Inc. He joined Pfizer and in time became Head of Ophthalmology Research. He is now Chief Scientific Officer at MingSight Pharmaceuticals. He contributed publications in peer-reviewed journals, is lead author on two patents and a contributor to a third patent. Dr. Niesman is a crucial member of Nano PharmaSolutions (NPS) Scientific Advisory Board because of his expertise in ocular pharmacology, ocular drug delivery and ocular drug development, a dosage form to which NPS intends devote a significant amount of its resources.
Dr. Timothy Day Senior Vice President & General Manager
GM of Daylight Solutions Laser Physics
Dr. Timothy Day is Senior Vice President and General Manager of DRS Daylight Solutions. Daylight Solutions is an advanced manufacturer of molecular detection and imaging products, serving markets that include industrial process control, medical diagnostics and defense and security using Mid IR lasers and sensor systems. Dr. Day has over 30 years’ experience in both technical and business management in the photonics industry. He has led engineering, research, product development, manufacturing, and marketing operations.
Dr. Day began his career in 1990 as a cofounder of New Focus, where he served until the sale of the company to Bookham Technologies PLC in 2004. In 2004, Dr. Day cofounded Daylight Solutions where he served as CEO until its merger with Leonardo DRS in 2017.
Dr. Day actively participates on the boards for the following companies: Northern Colorado Veterans Resource Center, Cold Quanta and IRSweep. Dr. Day holds both a BS and an MS in Physics from San Diego State University and a PhD in Electrical Engineering from Stanford University.